| Literature DB >> 32747348 |
Victoria Leclercq1, Charlotte Beaudart2, Sara Ajamieh2, Ezio Tirelli3, Olivier Bruyère2.
Abstract
OBJECTIVES: Meta-analyses (MAs) are often used because they are lauded to provide robust evidence that synthesises information from multiple studies. However, the validity of MA conclusions relies on the procedural rigour applied by the authors. Therefore, this meta-research study aims to characterise the methodological quality and meta-analytic practices of MAs indexed in PsycINFO.Entities:
Keywords: epidemiology; public health; statistics & research methods
Mesh:
Year: 2020 PMID: 32747348 PMCID: PMC7402002 DOI: 10.1136/bmjopen-2019-036349
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
General characteristics of the MAs
| Characteristics | Category | N | No. (Per cent) | Median (P25–P75) |
| Mention of the use of a guideline other than PRISMA | Moose | 23 | 17 (73.9) | |
| Mars | 2 (8.7) | |||
| Cochrane | 1 (4.35) | |||
| Quorom | 1 (4.35) | |||
| Strobe | 1 (4.35) | |||
| Centre for reviews and dissemination | 1 (4.35) | |||
| Open access | Yes | 206 | 20 (9.7) | |
| Protocol registration | Yes | 206 | 15 (7.3) | |
| Cochrane MA | Yes | 206 | 1 (0.5) | |
| Presence of a search strategy | Yes | 206 | 81 (39.3) | |
| Presence of a linguistic bias | Yes | 206 | 96 (46.6) | |
| Use of statistical software | Yes | 170 (82.5) | ||
| Statistical software used | CMA | 193 | 87 (45.1) | |
| STATA | 30 (15.6) | |||
| Revman | 29 (15) | |||
| SPSS | 17 (8.8) | |||
| R | 10 (5.2) | |||
| SAS | 4 (2.1) | |||
| Other | 17 (8.8) | |||
| No. of studies included in the first MA | 1–3 studies | 206 | 11 (5.3) | |
| 4–9 studies | 57 (27.7) | |||
| ≥10 studies | 138 (67) | |||
| Assessment of the risk of bias (RoB) in individual studies | Yes | 206 | 111 (53.9) | |
| Tool used to assess the risk of bias | RoB tool | 95 | 36 (37.9) | |
| Newcastle-Ottawa Scale (NOS) | 14 (14.7) | |||
| Downs and Black | 6 (6.3) | |||
| Jadad | 5 (5.3) | |||
| Pedro | 5 (5.3) | |||
| Quadas | 5 (5.3) | |||
| Other | 24 (25.3) | |||
| Design of the included studies | Experimental | 60 (29.1) | ||
| Observational | 97 (47.1) | |||
| All types | 18 (8.7) | |||
| Not specified | 31 (15.1) | |||
| No. of authors | 1 author | 206 | 12 (5.8) | |
| 2–3 authors | 60 (29,1) | |||
| 4–6 authors | 98 (47.6) | |||
| ≥7 authors | 36 (17.5) | |||
| Continent of first author (workplace) | Africa | 206 | 1 (0.5) | |
| America | 64 (31.1) | |||
| Asia | 41 (19.9) | |||
| Europe | 70 (34) | |||
| Oceania | 30 (14.5) | |||
| Country of first author (workplace) | USA | 206 | 49 (23.8) | |
| Australia | 26 (12.6) | |||
| China | 22 (10.7) | |||
| England | 22 (10.7) | |||
| Netherlands | 15 (7.3) | |||
| Canada | 13 (6.3) | |||
| Germany | 11 (5.3) | |||
| Other (<11 reviews/country, 25 countries) | 48 (23.3) | |||
| H index of first author | 205 | 5 (2–12) | ||
| H index of last author | 195 | 22 (10–35) | ||
| Experience with MAs of the first author | Years | 206 | 2 (1–5) | |
| Affiliation of the first author | University | 206 | 189 (91.8) | |
| Declaration of conflicts of interest | Yes | 206 | 129 (62.6) | |
| Management of conflicts of interest | None | 206 | 114 (55.3) | |
| Described how they managed | 15 (7.3) | |||
| Not indicated | 77 (37.4) | |||
| Journal impact factor (2016) | 0.0–5.0 | 200 | 148 (71.9) | |
| 5.1–10.0 | 45 (21.8) | |||
| 10.1–15.0 | 1 (0.5) | |||
| >15.0 | 5 (2.4) | |||
| No impact factor | 7 (3.4) | |||
| Impact factor | 200 | 3.3 (2.3–5.2) | ||
| PRISMA-endorsing journal | Yes | 206 | 61 (29.6) | |
| Limitation of words | Yes | 206 | 130 (63.1) | |
| Methodological quality | ||||
| AMSTAR 2 tool | High quality | 206 | 1 (0.5) | |
| Moderate quality | 2 (1) | |||
| Low quality | 8 (4) | |||
| Critically low quality | 195 (94.5) | |||
AMSTAR2, A MeaSurement Tool to Assess systematic Reviews; MAs, meta-analyses; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 1Proportion of adherence to A MeaSurement Tool to Assess systematic Reviews (AMSTAR2) items. > : 7 critical domains identified by AMSTAR2. RoB, risk of bias.
Figure 2Impact of the explicit mention of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) on the methodological characteristics of MAs: the non-explicit mention of PRISMA group versus the explicit mention of PRISMA group. *Items statistically significantwith the Bonferroni correction for multiple testing (p≤0.003). AMSTAR2, MeaSurement Tool to Assess systematic Reviews; MAs, meta-analyses; RoB, risk of bias.